ClinicalTrials.gg
WithdrawnNCT01741909Updated Aug 31, 2016

Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy

An interventional study of education in Pneumonia, sponsored by HaEmek Medical Center, Israel. Withdrawn at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-31.

Sponsored by HaEmek Medical Center, Israel · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Due to recruiting issues
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Intravenous Azythromycin therapy is considerably more expensive than oral therapy. The investigators believe that intravenous therapy is prolonged more that necessary and that oral therapy can be used much earlier in the course of the disease. The investigators plan to check if that statement is true and intervene in order to shorten the intravenous therapy.

Read the detailed description

The study will be performed in two stages. First a retrospective review of medical files of 50 patients hospitalized in the Haemek Medical Center with severe community acquired pneumonia, treated with azythromycin. The files will be reviewed for the criteria clinical improvement, and for azythromycin therapy, oral or intravenous.

The results of this review will help us define the appropriate behavioral intervention in order to cause doctors to transfer from IV to PO therapy at the earliest appropriate time. An intervention such as posters, pharmacy overseeing etc will be introduced. 3 months after the intervention, an additional 50 files of pneumonia patients treated with azythromycin will be reviewed in order to check the efficacy of the intervention.

The Review board and the NIH will be updated about the intervention, as soon as the investigators have decided what intervention is appropriate

02

Conditions studied

  • Pneumonia

Keywords

  • azythromycin
  • community acquired pneumonia
  • intravenous
  • oral
03

In context

Pneumonia

2,072 studies on the registry are indexed under Pneumonia; 286 are open to participants now.

Browse Pneumonia studies →

Lead sponsor

HaEmek Medical Center, Israel is the lead sponsor of 237 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients hospitalized with community acquired pneumonia treated by azythromycin

Exclusion criteria

Exclusion Criteria:

  • Age under 18
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Before, After

    The intervention is educational

    Behavioral: education

Interventions

  • Behavioraleducation

    after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment

06

What researchers measure

Primary outcomes

  1. length of intravenous azythromycin treatment

    Time frame: 6 months

07

Study locations

1 site
  • Haemek Medical Center
    Afula, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01741909
Responsible party
Lee Goldstein (Lee Goldstein MD, HaEmek Medical Center, Israel) — Principal investigator
First posted
Dec 5, 2012
Start date
Dec 2012
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Aug 31, 2016

Study contacts

Lee H Goldstein, MD
principal investigator · haemek medical center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion